Alkermes plc (ALKS)
Automate Your Wheel Strategy on ALKS
With Tiblio's Option Bot, you can configure your own wheel strategy including ALKS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALKS
- Rev/Share 9.2638
- Book/Share 9.2504
- PB 3.2485
- Debt/Equity 0.049
- CurrentRatio 3.3332
- ROIC 0.2003
- MktCap 4955275050.0
- FreeCF/Share 2.9471
- PFCF 10.2897
- PE 13.922
- Debt/Assets 0.0356
- DivYield 0
- ROE 0.2541
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALKS | RBC Capital Mkts | -- | Sector Perform | -- | $40 | March 13, 2025 |
| Upgrade | ALKS | UBS | Sell | Neutral | $21 | $38 | March 4, 2025 |
| Initiation | ALKS | Deutsche Bank | -- | Buy | -- | $40 | Feb. 11, 2025 |
News
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Read More
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - …
Read More
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago.
Read More
Alkermes plc Reports First Quarter 2025 Financial Results
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year.
Read More
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives – DUBLIN , April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed …
Read More
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life – – 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thinking About Treatment Effect – DUBLIN , March 27, 2025 /PRNewswire/ -- People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' …
Read More
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
Read More
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Read More
Alkermes to Participate in Upcoming Investor Conferences
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual Health Care Conference Date/Time: Wednesday, March 5, 2025 at 9:50 a.m.
Read More
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Read More
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year.
Read More
Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Blair Jackson - Executive Vice President and Chief Operating Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI Jessica Fye - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Uy Ear - Mizuho Securities Troy Langford - TD Cowen Douglas Tsao …
Read More
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN , Feb. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year …
Read More
About Alkermes plc (ALKS)
- IPO Date 1991-07-16
- Website https://www.alkermes.com
- Industry Biotechnology
- CEO Mr. Richard F. Pops
- Employees 1800